These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 25915946)

  • 1. Molecular and Functional Characterization of Three Different Postzygotic Mutations in PIK3CA-Related Overgrowth Spectrum (PROS) Patients: Effects on PI3K/AKT/mTOR Signaling and Sensitivity to PIK3 Inhibitors.
    Loconte DC; Grossi V; Bozzao C; Forte G; Bagnulo R; Stella A; Lastella P; Cutrone M; Benedicenti F; Susca FC; Patruno M; Varvara D; Germani A; Chessa L; Laforgia N; Tenconi R; Simone C; Resta N
    PLoS One; 2015; 10(4):e0123092. PubMed ID: 25915946
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PIK3CA-related overgrowth spectrum (PROS): diagnostic and testing eligibility criteria, differential diagnosis, and evaluation.
    Keppler-Noreuil KM; Rios JJ; Parker VE; Semple RK; Lindhurst MJ; Sapp JC; Alomari A; Ezaki M; Dobyns W; Biesecker LG
    Am J Med Genet A; 2015 Feb; 167A(2):287-95. PubMed ID: 25557259
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [PIK3CA-related overgrowth syndrome (PROS)].
    Venot Q; Canaud G
    Nephrol Ther; 2017 Apr; 13 Suppl 1():S155-S156. PubMed ID: 28577738
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinical delineation and natural history of the PIK3CA-related overgrowth spectrum.
    Keppler-Noreuil KM; Sapp JC; Lindhurst MJ; Parker VE; Blumhorst C; Darling T; Tosi LL; Huson SM; Whitehouse RW; Jakkula E; Grant I; Balasubramanian M; Chandler KE; Fraser JL; Gucev Z; Crow YJ; Brennan LM; Clark R; Sellars EA; Pena LD; Krishnamurty V; Shuen A; Braverman N; Cunningham ML; Sutton VR; Tasic V; Graham JM; Geer J; Henderson A; Semple RK; Biesecker LG
    Am J Med Genet A; 2014 Jul; 164A(7):1713-33. PubMed ID: 24782230
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A comprehensive immunohistochemical and molecular approach to the PI3K/AKT/mTOR (phosphoinositide 3-kinase/v-akt murine thymoma viral oncogene/mammalian target of rapamycin) pathway in bladder urothelial carcinoma.
    Korkolopoulou P; Levidou G; Trigka EA; Prekete N; Karlou M; Thymara I; Sakellariou S; Fragkou P; Isaiadis D; Pavlopoulos P; Patsouris E; Saetta AA
    BJU Int; 2012 Dec; 110(11 Pt C):E1237-48. PubMed ID: 23107319
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Klippel-Trenaunay syndrome belongs to the PIK3CA-related overgrowth spectrum (PROS).
    Vahidnezhad H; Youssefian L; Uitto J
    Exp Dermatol; 2016 Jan; 25(1):17-9. PubMed ID: 26268729
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical and molecular data in cases of prenatal localized overgrowth disorder: major implication of genetic variants in PI3K-AKT-mTOR signaling pathway.
    Bourgon N; Carmignac V; Sorlin A; Duffourd Y; Philippe C; Thauvin-Robinet C; Guibaud L; Faivre L; Vabres P; Kuentz P;
    Ultrasound Obstet Gynecol; 2022 Apr; 59(4):532-542. PubMed ID: 34170046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. CLOVES syndrome: review of a PIK3CA-related overgrowth spectrum (PROS).
    Martinez-Lopez A; Blasco-Morente G; Perez-Lopez I; Herrera-Garcia JD; Luque-Valenzuela M; Sanchez-Cano D; Lopez-Gutierrez JC; Ruiz-Villaverde R; Tercedor-Sanchez J
    Clin Genet; 2017 Jan; 91(1):14-21. PubMed ID: 27426476
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A combination of genetic and biochemical analyses for the diagnosis of PI3K-AKT-mTOR pathway-associated megalencephaly.
    Negishi Y; Miya F; Hattori A; Johmura Y; Nakagawa M; Ando N; Hori I; Togawa T; Aoyama K; Ohashi K; Fukumura S; Mizuno S; Umemura A; Kishimoto Y; Okamoto N; Kato M; Tsunoda T; Yamasaki M; Kanemura Y; Kosaki K; Nakanishi M; Saitoh S
    BMC Med Genet; 2017 Jan; 18(1):4. PubMed ID: 28086757
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Megalencephaly syndromes and activating mutations in the PI3K-AKT pathway: MPPH and MCAP.
    Mirzaa GM; Rivière JB; Dobyns WB
    Am J Med Genet C Semin Med Genet; 2013 May; 163C(2):122-30. PubMed ID: 23592320
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted next-generation sequencing for detection of PIK3CA mutations in archival tissues from patients with Klippel-Trenaunay syndrome in an Asian population : List the full names and institutional addresses for all authors.
    Sasaki Y; Ishikawa K; Hatanaka KC; Oyamada Y; Sakuhara Y; Shimizu T; Saito T; Murao N; Onodera T; Miura T; Maeda T; Funayama E; Hatanaka Y; Yamamoto Y; Sasaki S
    Orphanet J Rare Dis; 2023 Sep; 18(1):270. PubMed ID: 37667289
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mosaic overgrowth with fibroadipose hyperplasia is caused by somatic activating mutations in PIK3CA.
    Lindhurst MJ; Parker VE; Payne F; Sapp JC; Rudge S; Harris J; Witkowski AM; Zhang Q; Groeneveld MP; Scott CE; Daly A; Huson SM; Tosi LL; Cunningham ML; Darling TN; Geer J; Gucev Z; Sutton VR; Tziotzios C; Dixon AK; Helliwell T; O'Rahilly S; Savage DB; Wakelam MJ; Barroso I; Biesecker LG; Semple RK
    Nat Genet; 2012 Jun; 44(8):928-33. PubMed ID: 22729222
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatic overgrowth disorders of the PI3K/AKT/mTOR pathway & therapeutic strategies.
    Keppler-Noreuil KM; Parker VE; Darling TN; Martinez-Agosto JA
    Am J Med Genet C Semin Med Genet; 2016 Dec; 172(4):402-421. PubMed ID: 27860216
    [TBL] [Abstract][Full Text] [Related]  

  • 17. De novo germline and postzygotic mutations in AKT3, PIK3R2 and PIK3CA cause a spectrum of related megalencephaly syndromes.
    Rivière JB; Mirzaa GM; O'Roak BJ; Beddaoui M; Alcantara D; Conway RL; St-Onge J; Schwartzentruber JA; Gripp KW; Nikkel SM; Worthylake T; Sullivan CT; Ward TR; Butler HE; Kramer NA; Albrecht B; Armour CM; Armstrong L; Caluseriu O; Cytrynbaum C; Drolet BA; Innes AM; Lauzon JL; Lin AE; Mancini GM; Meschino WS; Reggin JD; Saggar AK; Lerman-Sagie T; Uyanik G; Weksberg R; Zirn B; Beaulieu CL; ; Majewski J; Bulman DE; O'Driscoll M; Shendure J; Graham JM; Boycott KM; Dobyns WB
    Nat Genet; 2012 Jun; 44(8):934-40. PubMed ID: 22729224
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phenotypic and molecular characterization of five patients with PIK3CA-related overgrowth spectrum (PROS).
    Gökpınar İli E; Taşdelen E; Durmaz CD; Altıner Ş; Tuncalı T; Martinez-Glez V; Karabulut HG; Vural S; Ceylaner S; Acar MO; Ilgın Ruhi H
    Am J Med Genet A; 2022 Jun; 188(6):1792-1800. PubMed ID: 35238469
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Pagliazzi A; Oranges T; Traficante G; Trapani C; Facchini F; Martin A; Semeraro A; Perrone A; Filippeschi C; Giglio S
    Front Pediatr; 2021; 9():732836. PubMed ID: 34568242
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 22.